Fisher M, Sennikov S
Front Immunol. 2025; 16:1511671.
PMID: 39967659
PMC: 11832489.
DOI: 10.3389/fimmu.2025.1511671.
Aniogo E, Kujawski M, Awuah D, Cha S, Espinosa R, Hui S
Front Immunol. 2025; 15:1499471.
PMID: 39759518
PMC: 11695362.
DOI: 10.3389/fimmu.2024.1499471.
Fu Y, Feng C, Qin S, Xing Z, Liu C, Liu Z
Front Immunol. 2024; 15:1503099.
PMID: 39676874
PMC: 11638217.
DOI: 10.3389/fimmu.2024.1503099.
Zhang Z, Su M, Jiang P, Wang X, Tong X, Wu G
Cancer Med. 2024; 13(19):e70283.
PMID: 39377542
PMC: 11459502.
DOI: 10.1002/cam4.70283.
Chen L, Hu Y, Zheng B, Luo L, Su Z
Cancer Med. 2024; 13(17):e70164.
PMID: 39240157
PMC: 11378360.
DOI: 10.1002/cam4.70164.
Engineered T cells for Colorectal Cancer.
Rus Bakarurraini N, Kamarudin A, Jamal R, Abu N
Immunotherapy. 2024; 16(14-15):987-998.
PMID: 39229803
PMC: 11485792.
DOI: 10.1080/1750743X.2024.2391733.
Prognostic value of four immune-related genes in lower-grade gliomas: a biomarker discovery study.
Wang S, Wang Z, Liu Z, Wu J
Front Genet. 2024; 15:1403587.
PMID: 39192888
PMC: 11347950.
DOI: 10.3389/fgene.2024.1403587.
FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma.
Xiao W, Xu L, Wang J, Yu K, Xu B, Que Y
Cancer Gene Ther. 2024; 31(10):1571-1584.
PMID: 39183354
PMC: 11489081.
DOI: 10.1038/s41417-024-00823-2.
Cancer immunotherapies: A hope for the uncurable?.
Hamdan F, Cerullo V
Front Mol Med. 2024; 3:1140977.
PMID: 39086690
PMC: 11285639.
DOI: 10.3389/fmmed.2023.1140977.
Synthetic Cells and Molecules in Cellular Immunotherapy.
Lin H, Li C, Zhang W, Wu B, Wang Y, Wang S
Int J Biol Sci. 2024; 20(8):2833-2859.
PMID: 38904025
PMC: 11186374.
DOI: 10.7150/ijbs.94346.
The Unprecedented Success of Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Hematological Malignancies.
Dhaliwal S, Gill F, Hamid P
Cureus. 2024; 16(5):e59951.
PMID: 38854249
PMC: 11162278.
DOI: 10.7759/cureus.59951.
Advances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update.
Moaveni A, Amiri M, Shademan B, Farhadi A, Behroozi J, Nourazarian A
Front Mol Biosci. 2024; 11:1382190.
PMID: 38836106
PMC: 11149429.
DOI: 10.3389/fmolb.2024.1382190.
Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations.
Martin-Antonio B, Blanco B, Gonzalez-Murillo A, Hidalgo L, Minguillon J, Perez-Chacon G
Front Immunol. 2024; 15:1386856.
PMID: 38779672
PMC: 11109416.
DOI: 10.3389/fimmu.2024.1386856.
The CD4 transmembrane GGXXG and juxtamembrane (C/F)CV+C motifs mediate pMHCII-specific signaling independently of CD4-LCK interactions.
Lee M, Tuohy P, Kim C, Yost P, Lichauco K, Parrish H
Elife. 2024; 12.
PMID: 38639990
PMC: 11031086.
DOI: 10.7554/eLife.88225.
Adoptive T cell therapy for ovarian cancer.
Gitto S, Ihewulezi C, Powell Jr D
Gynecol Oncol. 2024; 186:77-84.
PMID: 38603955
PMC: 11216867.
DOI: 10.1016/j.ygyno.2024.04.001.
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy.
Shao W, Yao Y, Yang L, Li X, Ge T, Zheng Y
Exp Hematol Oncol. 2024; 13(1):37.
PMID: 38570883
PMC: 10988985.
DOI: 10.1186/s40164-024-00504-8.
Update on current and new potential immunotherapies in breast cancer, from bench to bedside.
Alaluf E, Shalamov M, Sonnenblick A
Front Immunol. 2024; 15:1287824.
PMID: 38433837
PMC: 10905744.
DOI: 10.3389/fimmu.2024.1287824.
Nanofibrous MultiDomain Peptide Hydrogels Provide T Cells a 3D, Cytocompatible Environment for Cell Expansion and Antigen-Specific Killing.
Leyva-Aranda V, Singh S, Telesforo M, Young S, Yee C, Hartgerink J
ACS Biomater Sci Eng. 2024; 10(3):1448-1460.
PMID: 38385283
PMC: 10955686.
DOI: 10.1021/acsbiomaterials.3c01617.
Augmenting regulatory T cells: new therapeutic strategy for rheumatoid arthritis.
Zhang J, Liu H, Chen Y, Liu H, Zhang S, Yin G
Front Immunol. 2024; 15:1312919.
PMID: 38322264
PMC: 10844451.
DOI: 10.3389/fimmu.2024.1312919.
Nursing care of patients with relapsed and refractory multiple myeloma treated with B-cell mature antigen-targeted universal chimeric antigen receptor T cells.
Dai Y, Tang F, Mao Y, He N, Yu M, Zhang M
Medicine (Baltimore). 2023; 102(47):e36067.
PMID: 38013297
PMC: 10681383.
DOI: 10.1097/MD.0000000000036067.